Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
Bogdan Popescu, Matthew F. Jones, Madison Piao, Elaine Tran, Andrew Koh, Isabelle Lomeli, Cheryl A.C. Peretz, Natália Faraj Murad, Sydney Abelson, Carolina Morales, José M. Rivera, Yana Pikman, Michael L. Cheng, Aaron C. Logan, Elliot Stieglitz, Catherine Choy Smith
This study evaluates RMC-7977, a RAS(ON) inhibitor, showing efficacy against RAS-driven resistance in AML and potential for combination therapies.
bioRxiv · Jun 10, 2025 · PreprintCancer Biology